Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Pirfenidone may protect against progression, death in idiopathic pulmonary fibrosis

12 Dec 2018

Treatment with pirfenidone may lead to significantly reduced risks of multiple progression events and death in patients with idiopathic pulmonary fibrosis (IPF), according to a study.

Researchers used data from the phase III trials ASCEND and CAPACITY and identified patients (n=1,247; mean age 68 years; 74.4 percent male) treated with pirfenidone 2,403 mg/day (n=623) or placebo (n=624). The main outcome was disease progression events over 12 months.

Disease progression events were characterized by a relative decline in % predicted forced vital capacity (FVC) ≥10 percent, absolute decline in 6-metre walking distance (6MWD) ≥50 m, respiratory hospitalization or death from any cause.

Based on pooled data, the most common disease progression events were declines in % predicted FVC (202 vs 304 events) and in 6MWD (265 vs 348 events), both occurring with greater frequency among patients on pirfenidone.

However, significantly fewer patients who received pirfenidone vs placebo experienced >1 progression event (17.0 percent vs 30.1 percent; p<0.0001) or died following ≥1 progression event (2.1 percent vs 6.3 percent; p=0.0002).

Compared with placebo, pirfenidone was associated with a lower risk of experiencing a single progression event (hazard ratio [HR], 0.71; 95 percent CI, 0.61–0.82; p<0.0001) and a second progression event (HR, 0.53; 0.42–0.67; p<0.0001).

The present data indicate that continued treatment with pirfenidone confers a benefit in IPF despite the occurrence of any single disease progression event, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.